Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Jun 2 · above the Ichimoku cloud · RSI 55 · MACD below its signal
| 9.40 | 52-week high | +12.98% |
| 8.65 | R3 (classic) | +4.01% |
| 8.53 | R2 (classic) | +2.48% |
| 8.49 | Previous week high | +2.04% |
| 8.42 | R1 (classic) | +1.24% |
| 8.40 | Previous day high | +0.96% |
| 8.40 | Previous month high | +0.96% |
| 8.32 | Price now | |
| 8.30 | Pivot | −0.28% |
| 8.19 | S1 (classic) | −1.52% |
| 8.17 | Previous day low | −1.80% |
| 8.07 | S2 (classic) | −3.04% |
| 7.96 | S3 (classic) | −4.29% |
| 7.90 | Previous week low | −5.05% |
| 7.85 | Previous month low | −5.65% |
| 4.00 | 52-week low | −51.92% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $610.9K | 0.00% | 99.33K | −2.1% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a HBIO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Snider WilliamDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| Jun 8, 2026 | Gagnon Robert EDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| Jun 8, 2026 | Eade Katherine AnneDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| Jun 8, 2026 | Benson Seth BenjaminDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| Jun 8, 2026 | Denelsky Stephen JDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| Mar 19, 2026 | Frost Mark TChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Mar 19, 2026 | Duke John D.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Mar 16, 2026 | Denelsky Stephen JDirector | Purchase at price 4.87 per share. | 10K | $48.70K |
| Mar 16, 2026 | Snider WilliamDirector | Purchase at price 0.50 - 4.85 per share. | 21K | $47.38K |
| Mar 15, 2026 | Frost Mark TChief Financial Officer | Purchase at price 0.50 per share. | 5K | $2.50K |
| Mar 15, 2026 | Duke John D.Chief Executive Officer | Purchase at price 0.50 per share. | 5K | $2.50K |
| Dec 16, 2025 | Snider WilliamDirector | — | 110K | — |
| Sep 4, 2025 | Denelsky Stephen JDirector | — | 110K | — |
| Aug 7, 2025 | Duke John D.Chief Executive Officer | — | 1.00M | — |
| Jul 15, 2025 | Gagnon Robert EDirector | — | 110K | — |
| Jul 15, 2025 | Eade Katherine AnneDirector | — | 110K | — |
| Jul 15, 2025 | Benson Seth BenjaminDirector | — | 110K | — |
| May 11, 2025 | Frost Mark TChief Financial Officer | — | 100K | — |
TimeframesUp on the hourly, daily and weekly, down on the monthly.
over a rising 21 EMA, 21 over 50
over a rising 21 EMA, 21 over 50
over a rising 21 EMA, 21 over 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.4 | 22.0 | -20.2 | 31.0 | -7.8 | 4.6 | -0.8 | 33.0 | -2.3 | 5.1 | +24.2% | ||
| 2025 | -19.0 | -50.9 | -32.1 | -36.8 | 30.6 | -6.4 | 6.8 | 6.4 | -12.0 | 18.2 | 46.2 | -11.8 | −68.2% |
| 2024 | -17.8 | -1.6 | -2.1 | -9.9 | -17.0 | -10.1 | 12.3 | -10.0 | -6.6 | -12.6 | -6.4 | -4.1 | −60.6% |
| 2023 | 7.6 | -5.0 | 48.4 | 36.2 | -2.3 | -1.8 | -15.3 | -5.2 | -2.5 | 2.1 | -3.0 | 25.6 | +93.1% |
| 2022 | -17.4 | -7.2 | 15.0 | -15.9 | -29.9 | -1.6 | 4.4 | -12.2 | -22.4 | 5.1 | -4.8 | 8.2 | −60.7% |
| 2021 | 8.2 | -5.4 | 24.4 | 26.9 | 1.0 | 19.0 | -5.3 | 4.7 | -15.5 | 7.9 | -11.2 | 5.4 | +64.3% |
| 2020 | -2.6 | 9.1 | -31.8 | 24.4 | -4.0 | 17.4 | 0.3 | 7.7 | -10.1 | 12.3 | 16.0 | 9.4 | +40.7% |
| 2019 | 7.9 | 17.2 | 7.2 | -10.2 | -41.3 | -11.9 | 24.0 | 0.0 | 24.2 | -9.1 | 3.6 | 5.2 | −4.1% |
| 2018 | 42.4 | 0.0 | 6.4 | 15.0 | -23.5 | 21.6 | 6.5 | 4.4 | -11.8 | -24.6 | -0.3 | -19.5 | −3.6% |
| 2017 | -1.6 | -6.7 | -7.1 | -7.7 | -4.2 | 10.9 | 9.8 | 10.7 | 21.0 | -10.7 | -1.5 | 0.0 | +8.2% |
| 2016 | -14.4 | -7.4 | 9.8 | -1.7 | 22.9 | -21.6 | -0.3 | -4.9 | 0.4 | -11.8 | 2.1 | 24.5 | −12.1% |
| 2015 | -8.1 | 4.8 | 6.6 | -4.6 | 0.9 | 1.8 | -14.2 | -10.6 | -13.5 | -22.2 | 7.8 | 9.5 | −38.8% |
| 2014 | -6.0 | 10.4 | -2.9 | -11.0 | -2.4 | 10.4 | 1.5 | -2.2 | -9.5 | 17.4 | 2.5 | 15.2 | +20.6% |
| 2013 | 13.5 | 15.7 | -1.7 | -9.4 | -0.8 | -7.5 | 13.8 | -7.7 | 6.5 | 11.2 | 2.8 | 3.1 | +41.5% |
| 2012 | 4.9 | 2.2 | -5.5 | 1.8 | -10.3 | 5.3 | -1.9 | 3.5 | 10.4 | -5.0 | -2.0 | 11.2 | +13.2% |
| 2011 | 4.2 | 2.4 | 30.6 | 1.1 | -1.2 | -6.0 | -5.1 | -13.6 | -3.4 | 8.1 | -3.1 | -12.4 | −5.1% |
| 2010 | -3.4 | 1.2 | 10.9 | 8.0 | -12.7 | -2.5 | 1.4 | -4.4 | 10.1 | 3.7 | -0.5 | 4.1 | +14.3% |
| 2009 | -3.0 | 0.0 | 16.0 | -2.7 | 17.9 | 15.5 | 5.3 | -18.7 | 12.1 | -4.5 | -1.4 | 0.0 | +34.7% |
| 2008 | -3.9 | 4.3 | 8.9 | -1.6 | -2.4 | -3.1 | 7.1 | -8.0 | 1.5 | -33.3 | -34.5 | 30.5 | −42.1% |
| 2007 | 3.3 | -4.3 | -4.9 | 14.9 | -6.7 | 1.5 | -2.1 | -10.5 | -2.2 | 6.7 | -11.7 | 8.0 | −10.7% |
Buy / hold / sell counts
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.